Details
Category: Volume 08 Issue 05 May 2020
Hits: 911

Title: Association of metabolic parameters, lipid and cytokine profiling, androgens and insulin levels in Precancer and Prostate cancer: A cross-sectional study in north Indian set up

Authors: Reshu Tewari, Anurag Bajpai, Apul Goel, D.Dalela, C.Vij

 DOI: https://dx.doi.org/10.18535/jmscr/v8i5.58

Abstract

 

Introduction: Prostatic diseases are highly prevalent in men worldwide among which Prostate cancer (PCa) is a significant cause of morbidity and mortality especially in many western countries and second leading cause of death in India. Relationship between Prostate cancer, Precancer and obesity has been observed in previous studies, however it is unlikely in Indian scenario, but the possibility of its association with cytokines, lipids and androgens level derangement can’t be ignored. So, the study is planned to observe the association of metabolic outline, lipid and cytokines profiling, androgens, insulin in Precancer and in Prostate cancer risk and aggressiveness.

Material and Method: A cross-sectional study was conducted to observe the association of association of metabolic profile, lipid profile and levels of cytokines, androgens, insulin in PIN and PCa patients. 50 patients of PIN and 50 patients clinically proved and histologically diagnosed with prostate cancer were evaluated in the study.

Results: Association of Lipid profile, androgens levels and cytokines levels are significant in precancer and PCa. Leptin may potentiate the growth of cancer cells, adiponectin appears to have an opposite effect.

Conclusion: Adiponectin works as anticancer gene and leptin can potentiate the growth of prostate cancer. Cytokines (eg. leptin), lipids and androgens may serve as prognostic parameters for early detection of prostate cancer. This could lead to better understanding of the PCa and in future may help in improving clinical management of the patients.

Keywords: Cytokine, Androgens, Insulin, Precancer, Prostate cancer, Lipid Level, Lipid profile.

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. 
  1. Zeigler-Johnson, A.H. Walker, B. Mancke, E. Spangler, M. Jalloh and S. McBride et al., Hum Hered. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4, C.M. 2002; 54 :13-21.
  2. Kenneth J. Pienta and Peggy S. Esper. Risk Factors for Prostate Cancer. Ann Intern Med. 1993;118(10):793-803.
  3. Ward, A. Jemal, V. Cokkinides, G.K. Singh, C. Cardinez and A. Ghafoor et al., Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54(2):78-93.
  4. Garfinkel. Overweight and mortality. Cancer 1986;58:1826-9.
  5. M. Nomura and L.N. Kolonel. Prostate cancer: a current perspective. Epidemiol Rev. 1991;13:200–227.
  6. Gillitzer, S. Pahernik, C. Hampel, S. Petry, S.W. Melchior and J.W. Thuroff. Relationship between prostate cancer and serum dyslipidemia Urology 2005;66:13-14.
  7. Noel W. Clarke and Michael D. Brown. The Influence of Lipid Metabolism on Prostate Cancer Development and Progression: Is it Time for a Closer Look? Eur Urol. 2007; 52:17–9.
  8. Obralic N, Kulovac B. High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels. Bosn, J Basic Med Sci. 2011 Nov; 11 (4):223-7.
  9. Amling, Robert H. Riffenburgh, Leon Sun, Judd W. Moul, et al. Andrew K. Chung, David G. Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy Christopher L. McLeod Journal of Clinical Oncology ;2004: pp. 439-445.
  10. Freedland, William J, Aronson, Christopher J. Kane, et al. Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group Stephen Journal of Clinical Oncology; 2004: 446-453.
  11. Bassett, M. Cooperberg, N. Sadetsky, S. Silva, J. DuChane, D. Pasta, J. Chan, J. Anast, P. Carroll, C. Kane. Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology:2005;66(5):1060-5.
  12. Article adapted by Medical News Today from original press release. "Waist-hip Ratio Should Replace Body Mass Index as Indicator of Mortality Risk in Older People", American Journal of Clinical Nutrition. August 12, 2006.
  13. Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome Bernardo Léo Wajchenberg Endocrine Reviews 2000; 21: 697-738.
  14. The association of body mass index and prostate -specific antigen in a population-based study, J. Baillargeon, B.H. Pollock and A.R. Kristal et al., Cancer 2005; 103: 1092–1095.
  15. B. Barqawi, B.K. Golden and C. O'Donnell et al., Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program, Urology 2005;65:708–712.
  16. Cancer J.H. Fowke, L.B. Signorello and S.S. Chang et al., Effects of obesity  and height on  prostate -specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men, 2006;107:2361–2367.
  17. A. Gray, B. Delahunt and J.R. Fowles et al., Demographic and clinical factors as determinants of serum levels of prostate  specific antigen and its derivatives, Anticancer Res 2004;24 :2069–2072.
  18. H. Ku, M.E. Kim and N.K. Lee et al., Influence of age, anthropometry, and hepatic and renal function on serum prostate specific antigen levels in healthy middle-age men, Urology 2003;61:132–136.
  19. M. Werny, T. Thompson and M. Saraiya et al., Obesity is negatively associated with  prostate-specific antigen in US men, 2001-2004, Cancer  Epidemiol Biomarkers Prev 2007;16 : 70–76.
  20. L. Banez, R.J. Hamilton and A.W. Partin et al., Obesity -related plasma hemodilution and PSA concentration among men with prostate cancer, JAMA 2007;298:2275–2280.
  21. Reshu T, Rajender S, Natu SM, Apul G, Divakar D, Goel M.M. Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men – A cross-sectional study. cytokine 2013;63:130-134.
  22. Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998;76:25–28.
  23. Gotkas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005;65:1168–1172.
  24. Obesity and prostate cancer: a role for adipokines. Mistry T, Digby JE, Desai KM, Randeva HS. Eur Urol 2007;52:46 –53.
  25. W. Hsing, S. Chua, Y. Gao et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93 (2001): 783–791.
  26. Jay H. Fowke, Saundra Motley, Qi Dai, Raoul Concepcion, and Daniel A. Association between Biomarkers of Obesity and Risk of High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer - Evidence of Effect Modification by Prostate Size. Barocas. Cancer Lett. 2013; 328(2): 345–352.

Corresponding Author

Reshu Tewari